Rachel K. King
CIK 1589712 · President, CEO · last filed 2025-06-30
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$233.5K
Companies
3
Total Filings
34
Lifetime Open-Market Net
-$223.3K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Recent Filings · Page 2 of 4
34 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-06-13 | NVAX | Mixed | +3,100 | $0 | EDGAR |
| 2023-05-22 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-21 | NVAX | Exer (M) | +700 | $0 | EDGAR |
| 2022-06-14 | NVAX | Grant (A) | — | $0 | EDGAR |
| 2022-05-20 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-08-20 | NVAX | Exer (M) | +3,450 | $0 | EDGAR |
| 2021-06-29 | NVAX | Exer (M) | +6,900 | $0 | EDGAR |
| 2021-06-22 | NVAX | Grant (A) | — | $0 | EDGAR |
| 2021-05-21 | NVAX | Buy (P) | +700 | $97.7K | EDGAR |
| 2021-01-22 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Grant (A) | +96,250 | $0 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.